D.C.-based Danaher Corp. (NYSE: DHR) is buying California molecular diagnostics company Cepheid Inc. (NASDAQ: CPHD) for about $4 billion in cash.
The $53 per share price represents a 54 percent premium on its Friday closing price of $34.42 per share. The deal, expected to close in the fourth quarter, would constitute a sizable addition to Danaher’s $8.2 billion life sciences and medical testing and equipment business.
{iframe}http://www.bizjournals.com/washington/news/2016/09/06/danaher-buys-up-diagnostics-company-cepheid-for-4.html?ana=e_ae_set1&s=article_du&ed=2016-09-06&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1473262592&j=75695362{/iframe}